$ News

BioCryst: A Changed And Interesting Thesis For 2026

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

BioCryst to buy Astria Therapeutics for $700m in enterprise value

Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition

How the Astria Deal Is Shaping the New Story for BioCryst Pharmaceuticals

Sector Update: Health Care Stocks Higher Late Afternoon

Top Midday Decliners

Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings

12 Health Care Stocks Moving In Tuesday's Intraday Session

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Escalating US-China Trade Friction

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst to Acquire Astria in Deal Valued at $700 Million